文献速递神经肿瘤

儿童低级别胶质瘤:最新进展与持续挑战

Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
PubMed 文献 · Neuro Oncol · 2024-01-01

儿童低级别胶质瘤(pLGG)占儿童中枢神经系统肿瘤的30%-40%,相关发病率高但肿瘤相关死亡率相对较低,现被视为慢性疾病,功能结局与生活质量日益重要。国际儿童低级别胶质瘤联盟(iPLGGc)综述了其流行病学、组织学、分子特征、治疗范式、生存结局、功能结局、影像反应及持续挑战,并引出另外三篇关于临床前模型、早期临床试验共识框架及耐药/反弹/复发的文章。

要点

  • pLGG占儿童中枢神经系统肿瘤的30%-40%,肿瘤相关死亡率相对较低。
  • pLGG被视为慢性疾病,功能结局和生活质量测量至关重要。
  • 靶向抑制剂带来希望,但最佳使用方式及长期毒性未知。

核心结论

  • pLGG被视为慢性疾病,功能结局和生活质量测量至关重要;靶向抑制剂带来巨大希望,但如何最佳优化使用仍存挑战,且这些抑制剂的长期毒性仍未知。

研究设计与样本

  • 国际儿童低级别胶质瘤联盟(iPLGGc)由全球pLGG领域医生和科学家组成,本文提供pLGG当前最新进展概述,并作为另外三篇pLGG手稿的引言。

主要发现

  • pLGG占儿童所有中枢神经系统肿瘤的30%-40%,相关发病率高但肿瘤相关死亡率相对较低。
  • 关于这些肿瘤的大量数据已涌现,包括对其自然史和分子驱动因素的更好理解,为靶向抑制剂的使用铺平了道路。
  • 靶向抑制剂带来巨大希望,但如何最佳优化使用仍存挑战,长期毒性仍未知。

关键数值与推荐

  • pLGG占儿童所有中枢神经系统肿瘤的30%-40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 靶向抑制剂的最佳使用方式仍存挑战,且这些抑制剂的长期毒性仍未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The most common childhood central nervous system (CNS) tumor is pediatric low-grade glioma (pLGG), representing 30%-40% of all CNS tumors in children. Although there is high associated morbidity, tumor-related mortality is relatively rare. pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures. A wealth of data has emerged about these tumors, including a better understanding of their natural history and their molecular drivers, paving the way for the use of targeted inhibitors. While these treatments have heralded tremendous promise, challenges remain about how to best optimize their use, and the long-term toxicities associated with these inhibitors remain unknown. The International Pediatric Low-Grade Glioma Coalition (iPLGGc) is a global group of physicians and scientists with expertise in pLGG focused on addressing key pLGG issues. Here, the iPLGGc provides an overview of the current state-of-the-art in pLGG, including epidemiology, histology, molecular landscape, treatment paradigms, survival outcomes, functional outcomes, imaging response, and ongoing challenges. This paper also serves as an introduction to 3 other pLGG manuscripts on (1) pLGG preclinical models, (2) consensus framework for conducting early-phase clinical trials in pLGG, and (3) pLGG resistance, rebound, and recurrence.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Fangusaro J, Jones DT, Packer RJ, et al. Pediatric low-grade glioma: State-of-the-art and ongoing challenges. Neuro Oncol. 2024. PMID: 37944912. doi:10.1093/neuonc/noad195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。